Felix Lourdes 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Apr 17, 2026
Research Summary
AI-generated summary of this filing
Lixte (LIXT) Director Felix Lourdes Receives Award
What Happened
Felix Lourdes, a director of Lixte Biotechnology Holdings, received an award of 25,000 restricted stock units (RSUs) on April 15, 2026 in exchange for the cancellation of 25,000 stock options. The RSUs vest immediately and each RSU represents a contingent right to one share upon vesting. No purchase price or sale proceeds are reported (prices listed as N/A).
Key Details
- Transaction date: April 15, 2026 (Form 4 filed April 17, 2026 — timely).
- Reported transactions: Award/Acquisition (code A) — 25,000 RSUs; Disposition to issuer (code D, derivative) — cancellation of 25,000 options.
- Price/Value: Not reported (N/A) for both transactions.
- Shares owned after transaction: The filing does not disclose Lourdes’s total shares owned after these transactions.
- Footnotes: The options were canceled pursuant to a Stock Option Cancellation Agreement dated April 15, 2026 in exchange for 25,000 RSUs that vest immediately (each RSU converts to one share upon vesting). The canceled options had previously provided for 50% vesting at grant and the remaining 50% vesting in quarterly installments beginning March 31, 2026.
Context
RSUs are a form of equity compensation that entitle the holder to receive shares upon vesting; because these RSUs vest immediately, the grant effectively confers a right to 25,000 shares subject to any settlement or transfer restrictions. This filing reflects a substitution of equity compensation (options → RSUs) rather than a market purchase or sale; such awards are common as part of executive/director compensation and do not by themselves indicate a buy or sell opinion by the insider.
Insider Transaction Report
- Award
Common Stock
[F1]2026-04-15+25,000→ 25,000 total - Disposition to Issuer
Stock Option (right to buy)
[F1][F2]2026-04-15−25,000→ 0 totalExercise: $4.05Exp: 2030-12-24→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on December 24, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.
- [F2]The canceled Options provided for vesting 50% on the grant date, the remaining 50% vesting in equal installments of 12.5% on March 31, 2026 and on the last date of each subsequent calendar quarter thereafter until fully vested.